Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy

Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

"The rationale of chemoradiotherapy after preoperative chemotherapy is to combine systemic and loco-regional treatments to reduce the risk of recurrent disease and improve outcomes," said the study's principal investigator Professor Marcel Verheij from the Netherlands Cancer Institute.

Peri-operative (pre- and post-operative) chemotherapy are the current standard of treatment for gastric cancer, but previous studies have suggested that post-operative chemoradiotherapy alone may improve outcomes to a similar extent.

In this phase III study, 788 patients with stage Ib-IVa resectable were randomized upfront and were all given pre-operative chemotherapy consisting of three courses of epirubicin, a platinum compound (cisplatin or oxaliplatin) and capecitabine.

After surgery, patients randomized to the 'standard' arm continued with another three courses of the same chemotherapy regime, while the others received chemoradiotherapy involving 45 Gy in 25 fractions combined with weekly cisplatin and daily capecitabine.

Researchers found a five-year survival rate of 40.8% in the chemotherapy arm, and 40.9% in the chemoradiotherapy arm, showing equivalent efficiency between the two treatment options.

There was a higher incidence of grade 3 or higher hematological adverse events in the chemotherapy arm (44% v 34%) but a higher incidence of gastrointestinal adverse events in the chemoradiotherapy arm (42% v 37%).

While the surgical quality was very high in the study, researchers noted that a significant number of patients did not start or complete the full course of either chemotherapy or chemoradiotherapy; 52% in the chemotherapy arm, and 47% in the chemoradiotherapy arm.

Professor Verheij said the team had anticipated a better outcome from the post-operative chemoradiotherapy arm compared to the peri-operative chemotherapy arm, but said subgroup analyses may identify specific patient populations who will benefit from either approach.

Commenting on the findings, Dr Dirk Arnold, from the Instituto CUF de Oncologia in Lisbon, Portugal, said, "it is well known that only a limited number are good candidates for any post-operative treatment following gastrectomy, so any post-operative treatment intensification may not be the right strategy."

"Despite the identification of subgroups benefitting from this approach with postoperative chemoradiation, the strategy should prompt into an intensification of the pre-operative treatment, and already other trials are evaluating different approaches, including chemoradiation in this setting, compared to standard alone," Dr Arnold said.

More information: LBA-02: A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study will be presented by Marcel Verheij during Session VI: Gastric Cancer on Thursday, 30 June 2016, 11:30 (CEST).

Citation: Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy (2016, June 30) retrieved 28 March 2024 from https://medicalxpress.com/news/2016-06-chemoradiotherapy-surgery-gastric-cancer-similar.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer

12 shares

Feedback to editors